These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37196544)

  • 41. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
    Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
    Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration.
    Kim NI; Park MH; Kweon SS; Lee JS
    Pathobiology; 2020; 87(3):179-192. PubMed ID: 32088722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
    Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
    Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B7-H3 in tumors: friend or foe for tumor immunity?
    Li G; Quan Y; Che F; Wang L
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switchable CAR T cell strategy against osteosarcoma.
    Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
    Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
    Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
    Barach YS; Lee JS; Zang X
    Trends Mol Med; 2011 Jan; 17(1):47-55. PubMed ID: 20971039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.
    Li N; Spetz MR; Li D; Ho M
    Pharmacol Ther; 2021 Jul; 223():107892. PubMed ID: 33992682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.
    Liu HJ; Du H; Khabibullin D; Zarei M; Wei K; Freeman GJ; Kwiatkowski DJ; Henske EP
    Nat Commun; 2023 Mar; 14(1):1214. PubMed ID: 36869048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.